These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16874922)

  • 1. The Critical Path to New Medicines: data sharing.
    Altern Lab Anim; 2006 Jun; 34(3):273-4. PubMed ID: 16874922
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical product development and regulatory science for the 21st century: the critical path vision and its impact on health care.
    Buckman S; Huang SM; Murphy S
    Clin Pharmacol Ther; 2007 Feb; 81(2):141-4. PubMed ID: 17259935
    [No Abstract]   [Full Text] [Related]  

  • 3. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macro trends in pharmaceutical innovation.
    Cohen FJ
    Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular medicine. NIH dives into drug discovery.
    Couzin J
    Science; 2003 Oct; 302(5643):218-21. PubMed ID: 14551416
    [No Abstract]   [Full Text] [Related]  

  • 6. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery.
    Kennedy D
    Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges associated with the development, manufacturing, and delivery of cellular medicines.
    Preti RA
    Cancer J; 2001; 7 Suppl 2():S62-6. PubMed ID: 11777266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug target validation: Hitting the target.
    Smith C
    Nature; 2003 Mar; 422(6929):341, 343, 345 passim. PubMed ID: 12646927
    [No Abstract]   [Full Text] [Related]  

  • 11. Toward more effective drug regulation.
    Schmidt AM
    FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug discovery: the leading edge.
    Chapman T
    Nature; 2004 Jul; 430(6995):109-15. PubMed ID: 15229608
    [No Abstract]   [Full Text] [Related]  

  • 13. Securing the US pharmaceutical supply.
    Somberg JC
    Am J Ther; 2008; 15(3):197. PubMed ID: 18496255
    [No Abstract]   [Full Text] [Related]  

  • 14. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 15. A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association.
    Chetty RK; Ozer JS; Lanevschi A; Schuppe-Koistinen I; McHale D; Pears JS; Vonderscher J; Sistare FD; Dieterle F
    Clin Pharmacol Ther; 2010 Aug; 88(2):260-2. PubMed ID: 20592723
    [No Abstract]   [Full Text] [Related]  

  • 16. World agencies try to stem flood of fake drugs.
    Surendran A
    Nat Med; 2004 Feb; 10(2):111. PubMed ID: 14760401
    [No Abstract]   [Full Text] [Related]  

  • 17. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 19. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of mitochondrial toxicity testing in drug development.
    Dykens JA; Will Y
    Drug Discov Today; 2007 Sep; 12(17-18):777-85. PubMed ID: 17826691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.